Tokyo, Feb. 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060707) titled 'The effects of lactic acid bacteria ingestion on inflammation-related serum markers' on Feb. 26.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Meiji Co., Ltd.
Condition:
Condition - Healthy adults
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To assess response in serum IL 10 levels following lactic acid bacteria ingestion
Basic objectives2 - Efficacy
Intervention:
Interventions/Control_1 - Ingestion of lactic acid bacteria powder
Eligibility:
Age-lower limit - 30
years-old
Gender - Male
Key inclusion criteria - 1. Subjects who completed a previous study (UMIN000054363) and ingested a high dose of lactic acid bacteria powder
2. Subjects who provided written informed consent prior to participation
Key exclusion criteria - 1. milk allergy
2. Subjects who donated 200 mL of blood within 1 month or 400 mL of blood within 3 months
3. Subjects deemed unsuitable for the study by the principal investigator for any other reason
Target Size - 11
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 15 Day
Date of IRB - 2026 Year 01 Month 15 Day
Anticipated trial start date - 2026 Year 02 Month 26 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069450
Disclaimer: Curated by HT Syndication.
